What Seqalis does

Seqalis is a Belgian B2B laboratory services provider operating as a trademark of BIO.be S.A. and closely affiliated with the Institute of Pathology and Genetics (IPG) in Gosselies, Belgium. The company delivers high-quality testing and analytical services spanning anatomical pathology, cytogenomics and molecular biology for biopharma companies, academic researchers and healthcare institutions across Europe. Its core service portfolio includes T Cell Repertoire Sequencing via its patented qTCR-Seq platform developed by Dr Javier Carrasco at the Laboratory of Translational Oncology (IPG/GHdC), together with DNA Sequencing (WGS, WES), RNA Sequencing (with Ribo-Zero Plus), Digital/Quantitative/Fragment Analysis PCR, Histopathology including immunohistochemistry, Cytogenomics (Karyotyping, FISH, sWGS, SNP Array, Optical Genome Mapping via Bionano Saphyr), Biobanking and Custom Services. Operations run on Illumina sequencing platforms (MiniSeq, NextSeq 500/550, NextSeq 2000, NovaSeq 6000), Bio-Rad QX200 AutoDG ddPCR, and automated IHC platforms from Dako, Roche Ventana and Leica.

Seqalis makes money through quote-based professional services engagements - project fees and analysis charges for bespoke testing work contracted primarily by biopharma and academic clients, with prices quoted in euros (taxes included, transport excluded). Go-to-market is enterprise field sales combined with inbound inquiry capture via the website and digital marketing channels including LinkedIn, content marketing with downloadable brochures and ESMO poster presentations, and co-organized webinars with academic and industry partners. Customer segments are biopharma companies (drug development, clinical trials), researchers/academics (translational research, clinical studies) and healthcare institutions (clinical trials, precision medicine, patient stratification).

The company's competitive positioning rests on regulatory accreditations (ISO 9001:2015 under BIO.be by VERITAS and ISO 15189:2022 under IPG by BELAC, certificate 381-MED), the proprietary qTCR-Seq patent, an extensive clinical biobank of plasma, tissue, cell-free DNA, DNA and RNA samples, and over 70 years of combined team experience in routine testing and new test development. Notable strategic engagements include participation in the AURORA 2 breast cancer project led by the Breast International Group (17 hospitals, 8 European countries), the Oncode Accelerator Therapeutic Vaccines Workstream, and joint webinars with Institut de Duve (UCLouvain) and PDC-Line Pharma.

Name

Seqalis

Legal name

BIO.be S.A.

Website

https://seqalis.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Seqalis is a Belgian B2B laboratory services provider (a trademark of BIO.be S.A.) offering molecular biology, cytogenomics, histopathology, DNA/RNA sequencing, PCR and biobanking services, anchored by its patented qTCR-Seq immune repertoire platform, serving biopharma, academic researchers and healthcare institutions across Europe.

Ownership category

akta.pro rank

Product category

Clinical Laboratory Services

NAICS

Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Transcriptomics & Gene Expression Profiling Services (HLAGANAE)

akta.pro secondary industries

Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Molecular Cytogenetics & Genomic Variation Services (Karyotyping/FISH/aCGH/CNV) (HLAGANAJ), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Genomic sequencing services
• T cell receptor sequencing
• Cytogenomic testing
• Histopathology services
• Molecular biology testing

Headquarters

HQ city

Charleroi

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Laboratory Testing Services: B2B laboratory services providing molecular biology, anatomical pathology, and genetic analysis. Services include T cell repertoire sequencing, cytogenomics, histopathology, DNA/RNA sequencing, PCR, biobanking, and custom services. Revenue generated through project-based quotations and analysis fees.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Seqalis is a B2B laboratory services company providing high-quality genetic and molecular biology testing in Anatomical Pathology, Cytogenomics and Molecular Biology. Its core offerings include T Cell Repertoire Sequencing via the patented qTCR-Seq platform, DNA and RNA sequencing (WGS, WES, RNA-seq), cytogenomics (karyotyping, FISH, SNP array, optical genome mapping), histopathology with immunohistochemistry, PCR (digital, quantitative, fragment analysis), and biobanking services. The company delivers customized project-based analysis and R&D support to biopharma, academic researchers, and healthcare institutions from its Gosselies, Belgium facility.

Product overview

Seqalis is a laboratory services company offering a comprehensive portfolio of genetic and molecular biology testing services. The core offering includes T Cell Repertoire Sequencing (qTCR-Seq), their proprietary patented technology for immune repertoire characterization, alongside a full suite of cytogenomics services (Karyotyping, FISH, sWGS, SNP Array, Optical Genome Mapping), DNA/RNA sequencing, PCR services (Digital, Quantitative, and Fragment Analysis), histopathology including immunohistochemistry, biobanking, and custom laboratory services. The qTCR-Seq platform represents their flagship innovation, while the other services form an integrated laboratory testing ecosystem supporting research, diagnostics, and clinical studies.

Differentiator

Problem solved

Functional benefit

Products and services

• T Cell Repertoire Sequencing (qTCR-Seq) A patented quantitative unbiased technology platform enabling precise exploration and accurate characterization of T cell immune response by sequencing RNA and/or DNA, used for cancer immunotherapy development, biomarker discovery, vaccine efficacy, and autoimmune disease research.
• Cytogenomics Cytogenomic testing services including Karyotyping, FISH, Shallow Whole Genome Sequencing, SNP array, and Optical Genome Mapping using the Bionano Saphyr system for detection of chromosomal abnormalities and structural rearrangements.
• Histopathology Pathology services including immunohistochemistry (IHC) with several hundred tests available across cytology, dermatology, gynaecology, haematology, neurology and other specialties, delivered via Dako, Roche Ventana, and Leica automated platforms.
• DNA Sequencing DNA sequencing services including Whole Genome Sequencing (WGS) and Whole Exome Sequencing (WES) using Illumina instruments (MiniSeq, NextSeq 500/550, NextSeq 2000, NovaSeq 6000) for identification of genetic aberrations across coding and non-coding regions.
• RNA Sequencing RNA sequencing (RNA-seq) services using Illumina Total RNA Prep with Ribo-Zero Plus and Twist Biosciences, supporting gene expression, allele-specific expression, alternative splicing, and non-coding RNA detection.
• PCR (Digital, Quantitative, and Reverse Transcription PCR) PCR services including Digital PCR (ddPCR) using the QX200 AutoDG Droplet Digital PCR System, Quantitative PCR (qPCR) using QuantStudio 5 and LightCycler 480, and DNA Fragment Analysis using 3730 DNA Analyzer and SeqStudio Genetic Analyzer.
• Biobanking Biobanking services for collection, archiving, and storage of biospecimens and associated data, offering both physical biobanking (samples stored at the Seqalis biobank) and virtual biobanking (samples stored at the customer facility with mandatory information registered at the biobank).
• Custom Services Customized laboratory testing and R&D services supporting projects with specific testing requirements, product development advisory, and custom test development, validation, and implementation, drawing on over 70 years of combined experience in routine testing and new test development.

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core.

• Oncode AcceleratorcoreStrategic or Co-development Partner · 4 July 2026Seqalis contributes quantitative analytical expertise to the Oncode Accelerator Therapeutic Vaccines Workstream. Through its patented qTCR-Seq technology and collaborative approach, Seqalis strengthens the development of next-generation therapeutic cancer vaccines with robust, data-driven insights supporting innovation in cancer immunotherapy.
• Breast International Group (BIG)coreStrategic or Co-development Partner · 29 November 2023Seqalis participates in phase 2 of the AURORA project, led by BIG, focusing on IHC analysis and NGS sequencing using OncoDNA's OncoDEEP Kit. The collaboration involves 17 hospitals from 7 research groups across 8 European countries in the fight against breast cancer.
• Institut de Duve (UCLouvain)coreStrategic or Co-development Partner · 25 January 2023Collaborated with Seqalis on Live Expert Panel on Immunotherapies webinar. Dr Sophie Lucas, President of de Duve Institute, participated as expert panelist. Collaboration in immuno-oncology research and educational outreach.
• PDC-Line PharmacoreStrategic or Co-development Partner · 25 January 2023Collaborated on Live Expert Panel on Immunotherapies webinar alongside Seqalis and Institut de Duve. Eric Halioua (CEO) and Dr Joël Plumas (CSO) participated as expert panelists. Partnership in immuno-oncology drug development.
• Institute of Pathology and Genetics (IPG)coreStrategic or Co-development PartnerParent company and strategic partner. Seqalis operates in close collaboration with IPG, relying on pathologists' expertise across multiple specialties (cytology, dermatology, neurology, oncology, etc.). IPG provides ISO 15189-2022 accredited laboratory infrastructure. Seqalis shares expertise and facilities with IPG for innovation in health and biomedical research.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Emerging players

• Bionano Genomics: Bionano Genomics develops and commercializes the Saphyr Optical Genome Mapping platform used by Seqalis for structural-variant cytogenomic services. While primarily an instrument provider, Bionano also runs service work and competes with Seqalis where both offer OGM-based cytogenomics.

Broad incumbents

• Foundation Medicine: Foundation Medicine is a large-scale oncology genomics profiling company (FoundationOne CDx, etc.) serving biopharma companion diagnostic development and clinical oncology. Although it operates at broader scope than Seqalis, it sets the competitive benchmark for oncology biomarker lab services that Seqalis's IHC and NGS work supports.
• NeoGenomics Laboratories: NeoGenomics is a U.S.-based oncology-focused clinical laboratory offering cytogenetics (karyotyping, FISH, OGM), IHC, and molecular testing at scale. It overlaps with Seqalis's cytogenomics and histopathology service lines, though its menu is broader and its geographic reach is significantly larger.
• Genewiz (Azenta Life Sciences): Genewiz, now part of Azenta Life Sciences, is a global Sanger and next-generation sequencing services provider serving pharma, biotech, and academic labs. It is a broader incumbent peer competing on DNA/RNA sequencing and custom services with significantly greater scale and geographic reach than Seqalis.

Direct peers

• MedGenome: MedGenome is a genomics-driven clinical and research services provider offering sequencing, cytogenetics, and immuno-oncology biomarker assays to biopharma and clinical customers. It is a comparable specialty genomics services peer focused on translational and clinical research workflows.
• Personalis: Personalis provides immuno-oncology-focused genomics services, including its NeXT Personal liquid biopsy and tumor profiling assays used in clinical trials. Both companies serve biopharma immuno-oncology programs with specialty genomic assays, making Personalis a comparable peer despite its U.S. footprint.
• OncoDNA: OncoDNA is a Belgium-based oncology genomics company providing NGS-based tumor profiling (e.g., OncoDEEP, which Seqalis already uses in the AURORA 2 project). It is a directly comparable Belgian specialty genomics peer with overlapping customer segments in precision oncology.
• iRepertoire: iRepertoire provides TCR and BCR immune repertoire sequencing services to pharma, biotech, and academic researchers. Like Seqalis, it sells immune-repertoire sequencing as a specialty lab service to biopharma R&D customers, making it a directly comparable peer.
• Adaptive Biotechnologies: Adaptive Biotechnologies pioneered immunoSEQ and clonoSEQ, the most established commercial T cell receptor sequencing platforms used in immuno-oncology research and clinical trials. It is the closest direct competitor to Seqalis's patented qTCR-Seq offering, serving many of the same biopharma sponsors.
• Eurofins Genomics: Eurofins Genomics is a global DNA, RNA, and next-generation sequencing services provider offering WGS, WES, RNA-seq, and qPCR to biopharma and academic customers. It competes head-to-head with Seqalis's broader nucleic-acid sequencing and PCR service menu, though at substantially larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/seqalis

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Seqalis